SAMe-TT2R2 Score Calculator

Clinical calculation support · Verify results before clinical use

Warfarin Control Assessment

Select the option that best describes the patient. The score updates automatically.

0 Score / 8
S

Sex: female

Female sex contributes one point.

+1 point
A

Age under 60 years

Select yes only if the patient is younger than 60 years.

+1 point
M

Medical history: more than two comorbidities

Examples include hypertension, diabetes, coronary artery disease or myocardial infarction, peripheral artery disease, heart failure, prior stroke, pulmonary disease, and hepatic or renal disease.

+1 point
T

Treatment with interacting drugs

For example, concomitant amiodarone. Consider clinically relevant interactions with vitamin K antagonists.

+1 point
T₂

Tobacco use within the past two years

Current tobacco use or use within the previous two years contributes two points.

+2 points
R₂

Race: non-Caucasian

This is a component of the originally published score. Interpret cautiously because performance and applicability may vary across populations.

+2 points
0Score / 8
Predicted warfarin control
More favorable predicted control
Score 0–2: a greater likelihood of achieving adequate warfarin control, although individual TTR cannot be guaranteed.
Clinical interpretation

If warfarin is selected, use appropriate INR monitoring, education, and follow-up. Review the patient's clinical circumstances and anticoagulation indication.

The score estimates the likelihood of warfarin control; it does not calculate an individual TTR, stroke risk, or bleeding risk. For eligible patients with atrial fibrillation, DOACs are generally preferred over VKAs. DOACs are not appropriate substitutes in patients with mechanical heart valves or moderate-to-severe mitral stenosis.

About the SAMe-TT₂R₂ Score

The SAMe-TT₂R₂ score was developed to help identify patients with atrial fibrillation who may be less likely to achieve good anticoagulation control with a vitamin K antagonist such as warfarin. It is a decision-support aid, not a substitute for measured INR control or clinical assessment.

Variables and points

ComponentCriterionPoints
SexFemale+1
AgeUnder 60 years+1
Medical historyMore than two comorbidities+1
TreatmentInteracting drug, e.g. amiodarone+1
TobaccoUse within the past two years+2
RaceNon-Caucasian+2

Interpretation

ScoreInterpretationPractical implication
0–2More favorable likelihood of good warfarin controlWarfarin may be considered when otherwise appropriate; monitor INR and assess actual TTR.
>2Higher likelihood of suboptimal warfarin controlIf a VKA is used, consider closer review, education, and INR monitoring; reassess anticoagulant choice when eligible.

Important clinical context

  • Actual anticoagulation quality should be assessed using INR history and time in therapeutic range, rather than inferred from this score alone.
  • For atrial fibrillation, the usual VKA target INR is 2.0–3.0; a TTR above 70% is generally desirable.
  • DOACs are generally preferred over VKAs in eligible patients, but not for mechanical heart valves or moderate-to-severe mitral stenosis.
  • The original score includes race as a predictor. Its calibration and performance may vary between populations, so local applicability should be considered.

References

Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest. 2013;144(5):1555–1563. doi:10.1378/chest.13-0054
Hsu JC, et al. SAMe-TT₂R₂ score in the outpatient anticoagulation clinic to predict time in therapeutic range and adverse events. See the indexed article record for study details and references. PubMed record
Van Gelder IC, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2024;45(36):3314–3414. Guideline and DOI
Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2021;42(5):373–498. Guideline and DOI
Clinical disclaimer: This calculator is intended for clinical decision support and education. It does not replace clinician judgement, review of the indication for anticoagulation, INR monitoring, drug-interaction assessment, or shared decision-making. Do not start, stop, or switch anticoagulation based on this score alone. Consider local guidelines, contraindications, renal function, patient preferences, affordability, and eligibility for each anticoagulant.